TP53 and breast carcinoma: High expression levels of E2F6 have previously been associated with ER-negative/P53-positive breast carcinomas (Palacios et al., 2005) and triple-negative breast cancer, in which the negative regulator miR-185 is downregulated (Tang et al., 2014).